A Multimodal AI Agent for Ophthalmic Clinical Decision Support

Condition(s) studied

Investigational drug(s) / intervention(s)

EyeAgent AI system: EyeAgent is a multimodal AI agent assistant for ophthalmology that integrates imaging, electronic health records, and curated clinical knowledge. In this arm, EyeAgent supports clinicians in clinical consultation, including report generation, diagnostic interpretation, and treatment planning.

Study summary

This study is a multicenter randomized controlled trial evaluating the effectiveness and safety of EyeAgent, a multimodal artificial intelligence (AI) agent designed to assist ophthalmologists in clinical decision-making. Participants will be recruited from ophthalmology clinics and hospitals in Hong Kong and mainland China. The AI agent acts as a digital co-pilot, analyzing patient images and clinical history to provide diagnostic and management recommendations. The trial aims to determine whether the use of the AI agent improves diagnostic accuracy, treatment decision-making performance, report generation, workflow efficiency, and user satisfaction compared to standard clinical practice.

Eligibility

Primary outcome measure(s)

• Diagnostic accuracy rate — Immediately after the intervention.
  Proportion of diagnoses consistent with a reference expert panel.
• Rate of inappropriate treatment decisions — Immediately after the intervention.
  The frequency of treatment recommendations (e.g., injection, laser therapy, or observation) that deviate from clinical guidelines as determined by the senior expert panel gold standard. Expert adjudication is conducted post-hoc after the enrollment phase concludes.

Trial sites (1)

More The Hong Kong Polytechnic University trials in China

Other trials for the same condition